Ion Channels
It is widely recognised that, although ion channels underlie many potential opportunities across diverse indications, they remain under-exploited as a class of drug target. This is principally because other classes of target, including enzymes and GPCRs, have proven more accessible to conventional discovery technologies.
The utility of ion channels as targets for therapeutic intervention is broad and includes opportunities such as atrial fibrillation, overactive bladder, a variety of autoimmune disorders, cancer, pain as well as a number of CNS disorders amongst many others.
Xention is using its proprietary approach to develop novel therapies for atrial fibrillation. Our success to date suggests that our unique multi-disciplinary approach is effective and able to generate highly potent and selective drug candidates.
This approach can also be applied to other therapeutic areas where modulation of ion channels is predicted to have a therapeutic effect. One such area is autoimmune disease where the potassium channel Kv1.3 is considered valid intervention target for T-cell mediated autoimmune diseases.
In addition, we continue to work on a number of other ion channel targets with partners and collaborators.